Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Pelareorep in advanced pancreatic adenocarcinoma
NCT03723915Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pelareorep in pancreatic adenocarcinoma (PDAC), sponsored by Northwestern University. Started Nov 2018; status: terminated.
02
Drugs
pelareorep
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03723915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723915.